UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (date of earliest event reported): February 23, 2015

                                 AMERICANN, INC.
                      -------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                       000-54231                27-4336843
 -------------------------          ----------------          ---------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
              ----------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000


                             1550 Larimer, Ste. 264
                                Denver, CO 80202
                -------------------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
<PAGE>

Item 1.01.  Entry Into a Material Definitive Agreement

     On  September  21, 2014  AmeriCann  entered into two loan  agreements  with
Wellness  Group  Pharms,  LLC  ("WGP").  Subsequent  to  entering  into the loan
agreements  WGP,  applied to the state of Illinois  for  licenses to operate two
marijuana cultivation facilities under the Illinois Compassionate Use of Medical
Cannabis Pilot Program Act.

     On  February  2, 2015 WGP was  notified  that it was awarded one of the two
licenses for which it applied  under the  Illinois  act. The State only issued a
total of 18 cultivation and processing  licenses.  The  application  process for
cultivation licenses in Illinois was extremely competitive as only approximately
10% of those that applied were awarded licenses.

     Under the terms of the loan agreement  pertaining to the license awarded to
WGP,  AmeriCann  had  agreed to loan WGP up to  $4,700,000,  subject  to certain
conditions.  Proceeds  from the loan would be used to  construct  the  marijuana
cultivation facility and for start-up costs.

     On February 23, 2015 AmeriCann and WGP amended their agreement and expanded
the scope of their partnership.

     The amended  agreement  calls for  AmeriCann to serve as the developer of a
new facility to be called the Illinois  Medical  Cannabis Center  ("IMCC").  WGP
plans to use the IMCC to cultivate,  process and distribute  medical cannabis to
many of the state's 52 newly licensed medical dispensaries.

     When fully constructed,  the IMCC will contain approximately 285,000 square
feet  capable of  producing  an  estimated  50,000  pounds  annually  of medical
cannabis.  The cost of the entire project, when fully developed,  is expected to
be approximately $20 million.

     AmeriCann will serve as the project  developer and will own the IMCC,  plus
provide working capital funding and horticultural  assistance to WGP.  AmeriCann
will receive,  over a 12-year period, a 25% fee on all cannabis  produced at the
IMCC,  $240,000 annually in consulting fees and $6.00 per square foot in monthly
lease payments.

     AmeriCann provided initial funding of $600,000 to WGP on February 23, 2015.
Funds were used for the premium ($400,000) for a $2 million performance bond and
for the payment of a $200,000 state license fee.

     AmeriCann  intends  to  commence  construction  of the IMCC in March with a
first phase of  approximately  27,000  square  feet.  WPG's  initial  harvest is
projected  for late Fall 2015.  AmeriCann  plans to add  additional  cultivation
capacity as the Illinois Medical Cannabis Program develops.

     Additionally, AmeriCann has commenced development of comprehensive cannabis
infused product line. As a part of the amended agreement, AmeriCann will license
this proprietary  product brand to WGP. WGP, in turn, will process,  package and
distribute  infused  cannabis  products  to  licensed  medical  dispensaries  in
Illinois.  AmeriCann  will  receive a 20% royalty  from the sale of all cannabis
extractions and infused products.

                                       2
<PAGE>

     With a  population  of over  12.7  million  people,  Illinois  is the fifth
largest  state in the U.S.  and one of the largest to adopt a medical  marijuana
program.

     AmeriCann plans to develop comparable facilities in other states that allow
for the production and sale of medical  cannabis.  On January 14, 2015 AmeriCann
announced plans to acquire a 52.6 acre parcel of undeveloped land  approximately
47 miles  southeast  of Boston and  develop the  property  as the  Massachusetts
Medical Cannabis Center.

     Previously  AmeriCann  closed  on  a  $2,250,000  all  cash  purchase  of a
five-acre  parcel of land in  Denver,  Colorado  and plans to  develop it as the
Denver Medical  Cannabis  Center.  Plans for the project  include 125,000 square
feet of greenhouse and other  facilities.  The project has received  preliminary
approval from the local planning board.

     AmeriCann will need to secure  significant  additional  capital to complete
its  plans for the  Illinois  Medical  Cannabis  Center  and its  other  planned
projects.

     AmeriCann does not cultivate, process or sell cannabis. More information is
available at acaninfo.com

Item 9.01   Financial Statements and Exhibits

Exhibit Number     Description
--------------     -----------

   10.1            Loan Agreement, as amended, with Wellness Group Pharms, LLC

                                       3
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: March 2, 2015
                                      AMERICANN, INC.


                                      By: /s/ Timothy Keogh
                                         -------------------------------
                                         Timothy Keogh, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kwellpharm3-15.txt", "description": "8-K ITEM 1.01", "secsgml_size_bytes": 7150}]
{"company-data": {"conformed-name": "Americann, Inc.", "cik": "0001508348", "assigned-sic": "6770", "irs-number": "274336843", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54231", "film-number": "15666561"}, "business-address": {"street1": "1550 LARIMER", "street2": "SUITE 264", "city": "DENVER", "state": "CO", "zip": "80202", "phone": "(303) 839-0061"}, "mail-address": {"street1": "1550 LARIMER", "street2": "SUITE 264", "city": "DENVER", "state": "CO", "zip": "80202"}, "former-company": {"former-conformed-name": "Nevada Health Scan, Inc.", "date-changed": "20101220"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (date of earliest event reported): February 23, 2015

                                 AMERICANN, INC.
                      -------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                       000-54231                27-4336843
 -------------------------          ----------------          ---------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
              ----------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000

                             1550 Larimer, Ste. 264
                                Denver, CO 80202
                -------------------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
Item 1.01.  Entry Into a Material Definitive Agreement

     On  September  21, 2014  AmeriCann  entered into two loan  agreements  with
Wellness  Group  Pharms,  LLC  ("WGP").  Subsequent  to  entering  into the loan
agreements  WGP,  applied to the state of Illinois  for  licenses to operate two
marijuana cultivation facilities under the Illinois Compassionate Use of Medical
Cannabis Pilot Program Act.

     On  February  2, 2015 WGP was  notified  that it was awarded one of the two
licenses for which it applied  under the  Illinois  act. The State only issued a
total of 18 cultivation and processing  licenses.  The  application  process for
cultivation licenses in Illinois was extremely competitive as only approximately
10% of those that applied were awarded licenses.

     Under the terms of the loan agreement  pertaining to the license awarded to
WGP,  AmeriCann  had  agreed to loan WGP up to  $4,700,000,  subject  to certain
conditions.  Proceeds  from the loan would be used to  construct  the  marijuana
cultivation facility and for start-up costs.

     On February 23, 2015 AmeriCann and WGP amended their agreement and expanded
the scope of their partnership.

     The amended  agreement  calls for  AmeriCann to serve as the developer of a
new facility to be called the Illinois  Medical  Cannabis Center  ("IMCC").  WGP
plans to use the IMCC to cultivate,  process and distribute  medical cannabis to
many of the state's 52 newly licensed medical dispensaries.

     When fully constructed,  the IMCC will contain approximately 285,000 square
feet  capable of  producing  an  estimated  50,000  pounds  annually  of medical
cannabis.  The cost of the entire project, when fully developed,  is expected to
be approximately $20 million.

     AmeriCann will serve as the project  developer and will own the IMCC,  plus
provide working capital funding and horticultural  assistance to WGP.  AmeriCann
will receive,  over a 12-year period, a 25% fee on all cannabis  produced at the
IMCC,  $240,000 annually in consulting fees and $6.00 per square foot in monthly
lease payments.

     AmeriCann provided initial funding of $600,000 to WGP on February 23, 2015.
Funds were used for the premium ($400,000) for a $2 million performance bond and
for the payment of a $200,000 state license fee.

     AmeriCann  intends  to  commence  construction  of the IMCC in March with a
first phase of  approximately  27,000  square  feet.  WPG's  initial  harvest is
projected  for late Fall 2015.  AmeriCann  plans to add  additional  cultivation
capacity as the Illinois Medical Cannabis Program develops.

     Additionally, AmeriCann has commenced development of comprehensive cannabis
infused product line. As a part of the amended agreement, AmeriCann will license
this proprietary  product brand to WGP. WGP, in turn, will process,  package and
distribute  infused  cannabis  products  to  licensed  medical  dispensaries  in
Illinois.  AmeriCann  will  receive a 20% royalty  from the sale of all cannabis
extractions and infused products.

                                       2
With a  population  of over  12.7  million  people,  Illinois  is the fifth
largest  state in the U.S.  and one of the largest to adopt a medical  marijuana
program.

     AmeriCann plans to develop comparable facilities in other states that allow
for the production and sale of medical  cannabis.  On January 14, 2015 AmeriCann
announced plans to acquire a 52.6 acre parcel of undeveloped land  approximately
47 miles  southeast  of Boston and  develop the  property  as the  Massachusetts
Medical Cannabis Center.

     Previously  AmeriCann  closed  on  a  $2,250,000  all  cash  purchase  of a
five-acre  parcel of land in  Denver,  Colorado  and plans to  develop it as the
Denver Medical  Cannabis  Center.  Plans for the project  include 125,000 square
feet of greenhouse and other  facilities.  The project has received  preliminary
approval from the local planning board.

     AmeriCann will need to secure  significant  additional  capital to complete
its  plans for the  Illinois  Medical  Cannabis  Center  and its  other  planned
projects.

     AmeriCann does not cultivate, process or sell cannabis. More information is
available at acaninfo.com

Item 9.01   Financial Statements and Exhibits

Exhibit Number     Description
--------------     -----------

   10.1            Loan Agreement, as amended, with Wellness Group Pharms, LLC

                                       3
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: March 2, 2015
                                      AMERICANN, INC.

                                      By: /s/ Timothy Keogh
                                         -------------------------------
                                         Timothy Keogh, Chief Executive Officer